$MAZE News

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts

Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate

A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy

Maze Therapeutics Announces $150 Million Registered Offering

Maze Therapeutics Prices $150M Offering Of 5.54M Common Shares At $23.50 And 850K Pre-Funded Warrants At $23.499

Maze Therapeutics Prices $150M Offering Of 5.54M Common Shares At $23.50 And 850K Pre-Funded Warrants At $23.499

Truist Securities Maintains Buy on Maze Therapeutics, Lowers Price Target to $64

Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

JP Morgan Maintains Overweight on Maze Therapeutics, Raises Price Target to $58

After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease

Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%

BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829